[{"id":"0120dde7-7c4b-4e29-a71b-f2ed345c607b","source_candidate_id":null,"drug_name_canonical":"Rovalpituzumab tesirine","aliases":"Rova-T|SC16LD6.5","portfolio_group":"Group D (Discontinued)","target":"DLL3","resolved_target_symbol":"DLL3","antibody":"Rovalpituzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"DNA alkylator","payload_exact_name":"Tesirine (PBD dimer)","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"PBD dimer core (Tesirine class)","is_proxy_derived":false,"clinical_phase":"Phase 3","program_status":"Terminated","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Fail","key_risk_category":"Toxicity","key_risk_signal":"Severe Effusion / Sepsis","failure_mode":"Toxicity","primary_source_type":"Clinical Trial","primary_source_id":"NCT01901653","evidence_refs":"[{\"id\": \"NCT01901653\", \"type\": \"Clinical Trial\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.908425+00","updated_at":"2026-01-14 06:08:29.14347+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"026f2692-cb75-4fa5-906e-0c0f4244635e","source_candidate_id":null,"drug_name_canonical":"Gemtuzumab ozogamicin","aliases":"Mylotarg","portfolio_group":"Group A (Approved)","target":"CD33","resolved_target_symbol":"CD33","antibody":"Gemtuzumab","linker_family":"Cleavable","linker_trigger":"Acid-labile (Hydrazone)","payload_family":"DNA breaker","payload_exact_name":"Calicheamicin","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"Calicheamicin core","is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"VOD (Veno-occlusive disease)","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761060","evidence_refs":"[{\"id\": \"BLA 761060\", \"type\": \"FDA Label\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.000958+00","updated_at":"2026-01-14 06:08:28.528566+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"1eebfb7d-d153-45dd-bec2-2b9b1b6922e1","source_candidate_id":null,"drug_name_canonical":"Mirvetuximab soravtansine","aliases":"Elahere|IMGN853","portfolio_group":"Group A (Approved)","target":"FR alpha","resolved_target_symbol":"FOLR1","antibody":"Mirvetuximab","linker_family":"Cleavable","linker_trigger":"Disulfide (Redox)","payload_family":"Microtubule inh","payload_exact_name":"DM4 (Maytansinoid)","payload_smiles_raw":null,"payload_smiles_standardized":"CC(C)C(CS)NC(=O)C1CC2C(C(O1)C)OC(=O)CC(C(C(C(C(C(=C2)C)OC(=O)N)C)OC)O)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Ocular Toxicity","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761310","evidence_refs":"[{\"id\": \"BLA 761310\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:11:52.111+00","created_at":"2026-01-14 03:19:03.903748+00","updated_at":"2026-01-14 05:11:52.244802+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"213e806b-a494-4f94-a61d-6f1258da0a31","source_candidate_id":null,"drug_name_canonical":"Trastuzumab duocarmazine","aliases":"SYD985","portfolio_group":"Group B (Late)","target":"HER2","resolved_target_symbol":"ERBB2","antibody":"Trastuzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"DNA alkylator","payload_exact_name":"Duocarmycin","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"Duocarmycin/seco-DUBA core","is_proxy_derived":false,"clinical_phase":"Phase 3","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Caution","key_risk_category":"Toxicity","key_risk_signal":"Ocular Toxicity","failure_mode":null,"primary_source_type":"Review Paper","primary_source_id":"PMID: 37185211","evidence_refs":"[{\"id\": \"PMID: 37185211\", \"type\": \"Review Paper\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.610957+00","updated_at":"2026-01-14 06:08:28.949378+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"217b7150-0dc1-4a14-b078-5b55edbc4119","source_candidate_id":null,"drug_name_canonical":"Enfortumab vedotin","aliases":"Padcev|ASG-22ME","portfolio_group":"Group A (Approved)","target":"Nectin-4","resolved_target_symbol":"NECTIN4","antibody":"Enfortumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"MMAE (Auristatin)","payload_smiles_raw":null,"payload_smiles_standardized":"CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(C)C(=O)OC)NC(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Skin reactions (SJS/TEN)","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761144","evidence_refs":"[{\"id\": \"BLA 761144\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:10:17.788+00","created_at":"2026-01-14 03:19:03.498683+00","updated_at":"2026-01-14 05:10:17.921279+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"27756a59-985a-47af-821f-fd6773f3053c","source_candidate_id":null,"drug_name_canonical":"ABBV-400","aliases":"ABBV-400","portfolio_group":"Group B (Late)","target":"c-Met","resolved_target_symbol":"MET","antibody":"AbbVie mAb","linker_family":"Cleavable","linker_trigger":"Protease (Top1 linker)","payload_family":"Topo1 inhibitor","payload_exact_name":"Top1i novel","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"SN-38 core (assumed Topo1 inhibitor)","is_proxy_derived":false,"clinical_phase":"Phase 2","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Uncertain","key_risk_category":"Toxicity","key_risk_signal":"Anemia","failure_mode":null,"primary_source_type":"Clinical Trial","primary_source_id":"NCT06084481","evidence_refs":"[{\"id\": \"NCT06084481\", \"type\": \"Clinical Trial\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.513088+00","updated_at":"2026-01-14 06:08:29.494449+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"2f420b77-c7c8-48db-8c71-2bec8e156694","source_candidate_id":null,"drug_name_canonical":"Tisotumab vedotin","aliases":"Tivdak","portfolio_group":"Group A (Approved)","target":"Tissue Factor","resolved_target_symbol":"F3","antibody":"Tisotumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"MMAE (Auristatin)","payload_smiles_raw":null,"payload_smiles_standardized":"CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(C)C(=O)OC)NC(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Ocular Toxicity","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761208","evidence_refs":"[{\"id\": \"BLA 761208\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:10:43.672+00","created_at":"2026-01-14 03:19:03.697599+00","updated_at":"2026-01-14 05:10:43.803385+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"52ca8e5e-2232-454b-a15b-9a88500062a5","source_candidate_id":null,"drug_name_canonical":"Polatuzumab vedotin","aliases":"Polivy","portfolio_group":"Group A (Approved)","target":"CD79b","resolved_target_symbol":"CD79B","antibody":"Polatuzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"MMAE (Auristatin)","payload_smiles_raw":null,"payload_smiles_standardized":"CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(C)C(=O)OC)NC(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Peripheral Neuropathy","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761121","evidence_refs":"[{\"id\": \"BLA 761121\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:10:30.836+00","created_at":"2026-01-14 03:19:03.597375+00","updated_at":"2026-01-14 05:10:30.965753+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"55a43e08-891e-479f-9ffb-60c81d0392c5","source_candidate_id":null,"drug_name_canonical":"Vadastuximab talirine","aliases":"SGN-CD33A","portfolio_group":"Group D (Discontinued)","target":"CD33","resolved_target_symbol":"CD33","antibody":"Vadastuximab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"DNA alkylator","payload_exact_name":"PBD dimer (SGD-1882)","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"PBD dimer core (SGD-1882 variant)","is_proxy_derived":false,"clinical_phase":"Phase 3","program_status":"Terminated","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Fail","key_risk_category":"Safety","key_risk_signal":"Patient Death (AML)","failure_mode":"Safety","primary_source_type":"Clinical Trial","primary_source_id":"NCT02785900","evidence_refs":"[{\"id\": \"NCT02785900\", \"type\": \"Clinical Trial\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:05.008935+00","updated_at":"2026-01-14 06:08:29.263379+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"5f9f260b-0757-4b81-a642-e6bfc14e8143","source_candidate_id":null,"drug_name_canonical":"Trastuzumab emtansine","aliases":"Kadcyla|T-DM1","portfolio_group":"Group A (Approved)","target":"HER2","resolved_target_symbol":"ERBB2","antibody":"Trastuzumab","linker_family":"Non-cleavable","linker_trigger":"N/A","payload_family":"Microtubule inh","payload_exact_name":"DM1 (Maytansinoid)","payload_smiles_raw":null,"payload_smiles_standardized":"CC[C@H]1OC(=O)[C@H]([C@@H](C)[C@@H]2CC(=O)N([C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)O2)C)SCCO","payload_cid":"11542111","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Thrombocytopenia","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 125427","evidence_refs":"[{\"id\": \"BLA 125427\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:09:17.991+00","created_at":"2026-01-14 03:19:03.182349+00","updated_at":"2026-01-14 05:09:18.124953+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"6f04f7ba-c664-4267-b75e-acb29e0b8cad","source_candidate_id":null,"drug_name_canonical":"Telisotuzumab vedotin","aliases":"Teliso-V|ABBV-399","portfolio_group":"Group B (Late)","target":"c-Met","resolved_target_symbol":"MET","antibody":"Telisotuzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"MMAE (Auristatin)","payload_smiles_raw":null,"payload_smiles_standardized":"CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(C)C(=O)OC)NC(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Phase 3","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Neuropathy","failure_mode":null,"primary_source_type":"Clinical Trial","primary_source_id":"NCT05029882","evidence_refs":"[{\"id\": \"NCT05029882\", \"type\": \"Clinical Trial\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.400549+00","updated_at":"2026-01-14 06:08:28.835315+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"9e923f27-93b8-4e56-991c-fe9d79be22a3","source_candidate_id":null,"drug_name_canonical":"Datopotamab deruxtecan","aliases":"Dato-DXd|DS-1062","portfolio_group":"Group B (Late)","target":"TROP2","resolved_target_symbol":"TACSTD2","antibody":"Datopotamab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Topo1 inhibitor","payload_exact_name":"DXd","payload_smiles_raw":null,"payload_smiles_standardized":"COc1cc2c(cc1OC)C(=O)N3Cc4cc5c(cc4[C@@H]3[C@@H]2O)OCO5","payload_cid":"129268219","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Phase 3","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Uncertain","key_risk_category":"Toxicity","key_risk_signal":"Stomatitis / Mucositis","failure_mode":null,"primary_source_type":"Clinical Trial","primary_source_id":"NCT04656652","evidence_refs":"[{\"id\": \"NCT04656652\", \"type\": \"Clinical Trial\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.101601+00","updated_at":"2026-01-14 06:08:28.631837+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"aa7302c9-7c3b-44c4-a65e-61effc064924","source_candidate_id":null,"drug_name_canonical":"Farletuzumab ecteribulin","aliases":"MORAb-202","portfolio_group":"Group C (Novelty)","target":"FR alpha","resolved_target_symbol":"FOLR1","antibody":"Farletuzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"Eribulin","payload_smiles_raw":null,"payload_smiles_standardized":"C[C@H]1CCC[C@H]2C[C@@H]([C@H]([C@H](O2)[C@H]3C[C@@H]([C@@H]([C@H](O3)C=C[C@H]4C[C@@H](C[C@H](O4)CC(=C)[C@@H](C(=O)[C@@H]5C[C@@H]([C@H](O5)C[C@@H]6CC(=C)[C@@H]([C@H](O6)C[C@@H](C)O1)O)O)O)O)O)O)O)O","payload_cid":"11354606","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Phase 2","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Efficacy","key_risk_signal":"Lung Toxicity (Low grade)","failure_mode":null,"primary_source_type":"Review Paper","primary_source_id":"PMID: 38814723","evidence_refs":"[{\"id\": \"PMID: 38814723\", \"type\": \"Review Paper\"}]","gate_status":"ready_to_promote","is_final":false,"is_manually_verified":false,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":null,"finalized_at":null,"created_at":"2026-01-14 03:19:04.80895+00","updated_at":"2026-01-14 06:08:29.600034+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"b0613084-ecb4-4ce4-a972-65a414b41414","source_candidate_id":null,"drug_name_canonical":"Sacituzumab govitecan","aliases":"Trodelvy|IMMU-132","portfolio_group":"Group A (Approved)","target":"TROP2","resolved_target_symbol":"TACSTD2","antibody":"Sacituzumab","linker_family":"Cleavable","linker_trigger":"Acid-labile (pH)","payload_family":"Topo1 inhibitor","payload_exact_name":"SN-38","payload_smiles_raw":null,"payload_smiles_standardized":"CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC2=C1C=C(O)C=C2","payload_cid":"60953","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Severe Diarrhea / Neutropenia","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761115","evidence_refs":"[{\"id\": \"BLA 761115\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:09:59.527+00","created_at":"2026-01-14 03:19:03.398243+00","updated_at":"2026-01-14 05:09:59.669495+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"b0a0a8ab-0470-424b-b4cf-08f60a11cd70","source_candidate_id":null,"drug_name_canonical":"Brentuximab vedotin","aliases":"Adcetris|SGN-35","portfolio_group":"Group A (Approved)","target":"CD30","resolved_target_symbol":"TNFRSF8","antibody":"Brentuximab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Microtubule inh","payload_exact_name":"MMAE (Auristatin)","payload_smiles_raw":null,"payload_smiles_standardized":"CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N1CCCC1C(=O)NC(C)C(=O)OC)NC(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C","payload_cid":"56677881","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Peripheral Neuropathy","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 125388","evidence_refs":"[{\"id\": \"BLA 125388\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:09:42.069+00","created_at":"2026-01-14 03:19:03.290181+00","updated_at":"2026-01-14 05:09:42.206624+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"b73fe6cf-89fd-49fb-849b-bd031212afdb","source_candidate_id":null,"drug_name_canonical":"Trastuzumab deruxtecan","aliases":"Enhertu|DS-8201","portfolio_group":"Group A (Approved)","target":"HER2","resolved_target_symbol":"ERBB2","antibody":"Trastuzumab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"Topo1 inhibitor","payload_exact_name":"DXd","payload_smiles_raw":null,"payload_smiles_standardized":"COc1cc2c(cc1OC)C(=O)N3Cc4cc5c(cc4[C@@H]3[C@@H]2O)OCO5","payload_cid":"129268219","payload_inchi_key":null,"proxy_smiles_flag":false,"proxy_reference":null,"is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"ILD (Interstitial Lung Disease)","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761139","evidence_refs":"[{\"id\": \"BLA 761139\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:08:57.698+00","created_at":"2026-01-14 03:19:02.92001+00","updated_at":"2026-01-14 05:08:57.8362+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null},{"id":"c2c424e0-80d9-477c-88f1-b8ae3eb37f7e","source_candidate_id":null,"drug_name_canonical":"Loncastuximab tesirine","aliases":"Zynlonta|ADCT-402","portfolio_group":"Group A (Approved)","target":"CD19","resolved_target_symbol":"CD19","antibody":"Loncastuximab","linker_family":"Cleavable","linker_trigger":"Protease (Cathepsin)","payload_family":"DNA alkylator","payload_exact_name":"SG3199 (PBD dimer)","payload_smiles_raw":null,"payload_smiles_standardized":null,"payload_cid":null,"payload_inchi_key":null,"proxy_smiles_flag":true,"proxy_reference":"PBD dimer core (Tesirine class)","is_proxy_derived":false,"clinical_phase":"Approved","program_status":"Active","clinical_nct_id_primary":null,"clinical_nct_ids_secondary":"[]","outcome_label":"Success","key_risk_category":"Toxicity","key_risk_signal":"Edema / Effusion","failure_mode":null,"primary_source_type":"FDA Label","primary_source_id":"BLA 761169","evidence_refs":"[{\"id\": \"BLA 761169\", \"type\": \"FDA Label\"}]","gate_status":"final","is_final":true,"is_manually_verified":true,"field_verified":"{}","last_verified_at":null,"verified_by":null,"rdkit_mw":null,"rdkit_logp":null,"rdkit_tpsa":null,"rdkit_hbd":null,"rdkit_hba":null,"rdkit_qed":null,"finalized_by":"admin","finalized_at":"2026-01-14 05:11:00.219+00","created_at":"2026-01-14 03:19:03.802728+00","updated_at":"2026-01-14 05:11:00.364467+00","antibody_name_canonical":null,"antibody_format":null,"antibody_uniprot_id":null,"antibody_drugbank_id":null,"linker_smiles":null,"linker_id_ref":null,"is_proxy_payload":false,"proxy_payload_reference":null,"proxy_payload_evidence_refs":"[]","is_proxy_linker":false,"proxy_linker_reference":null,"is_proxy_antibody":false,"proxy_antibody_reference":null}]